Haijun Ma
About Haijun Ma
Haijun Ma serves as the Executive Director of Biostatistics, Safety, and Real World Evidence at Nektar Therapeutics, where he leads a team focused on Real World Data and Evidence to support clinical development. He has extensive experience in biostatistics, safety monitoring, and oncology strategy, having previously held positions at Amgen and Eli Lilly.
Work at Nektar Therapeutics
Haijun Ma serves as the Executive Director of Biostatistics, Safety, and Real World Evidence (RWE) at Nektar Therapeutics. In this role, he leads a team focused on Real World Data (RWD) and RWE, contributing to the company's clinical development and medical affairs initiatives. His responsibilities include providing statistical support for reimbursement and publications, as well as engaging in regulatory interactions and filing processes specifically for oncology products. Ma has been with Nektar Therapeutics since 2019.
Education and Expertise
Haijun Ma has an extensive educational background in statistics and biostatistics. He earned a Master’s degree in Statistics from Iowa State University, where he studied from 2001 to 2003. He later obtained a Ph.D. in Biostatistics from the University of Minnesota, completing his studies from 2003 to 2006. Additionally, he holds a Bachelor of Arts in Spanish from Nanjing University. His expertise includes program level strategy development, study design for oncology products, and safety monitoring.
Background
Before joining Nektar Therapeutics, Haijun Ma worked at Amgen as the Director of Biostatistics from 2006 to 2019, accumulating 13 years of experience in Thousand Oaks, California. He also completed a summer internship at Eli Lilly in 2005, where he gained valuable industry experience over an 11-month period. His career has been marked by a focus on biostatistics and safety in the pharmaceutical sector.
Achievements
Haijun Ma has played a significant role in building and leading a Real World Data and Real World Evidence team at Nektar Therapeutics. He is involved in licensing Real World Data to support clinical development and medical affairs. His contributions extend to leading statistical support for reimbursement and publications, as well as engaging in regulatory interactions for oncology products.